<DOC>
	<DOCNO>NCT02065557</DOCNO>
	<brief_summary>The purpose study demonstrate efficacy safety , assess pharmacokinetics adalimumab administer subcutaneously ( SC ) pediatric subject moderate severe ulcerative colitis ( UC ) .</brief_summary>
	<brief_title>Efficacy Safety Adalimumab Pediatric Subjects With Moderate Severe Ulcerative Colitis</brief_title>
	<detailed_description />
	<mesh_term>Ulcer</mesh_term>
	<mesh_term>Colitis , Ulcerative</mesh_term>
	<mesh_term>Colitis</mesh_term>
	<mesh_term>Adalimumab</mesh_term>
	<criteria>Diagnosis Ulcerative Colitis ( UC ) least 12 week prior screen , confirm endoscopy biopsy . Active ulcerative colitis Mayo Score 6 12 point endoscopy subscore 2 3 despite concurrent treatment oral corticosteroid immunosuppressant . Subject Crohn 's disease ( CD ) indeterminate colitis ( IC ) . Current diagnosis fulminant colitis and/or toxic megacolon . Subjects disease limited rectum ( ulcerative proctitis ) screen endoscopy . Chronic recur infection active Tuberculosis ( TB ) .</criteria>
	<gender>All</gender>
	<minimum_age>4 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Ulcerative Colitis</keyword>
	<keyword>adalimumab</keyword>
</DOC>